Literature DB >> 17222660

Cost-utility analysis of treatment algorithms for moderate grade vesicoureteral reflux using Markov models.

Michael H Hsieh1, Hubert S Swana, Laurence S Baskin, Maxwell V Meng.   

Abstract

PURPOSE: The optimal treatment algorithm for vesicoureteral reflux remains controversial. Previous decision analyses have attempted to determine the best approach solely from the cost or cure perspective but have not combined the goals of minimizing treatment and disease burden. We incorporated these considerations into a contemporary, comprehensive analysis of treatment for vesicoureteral reflux.
MATERIALS AND METHODS: We examined costs from the perspective of the medical institution, and utility from the perspective of parents of children with grades II and III vesicoureteral reflux. Cost-utility analysis using Markov modeling was performed to ascertain which of 5 treatment algorithms best minimized morbidity and cost. A higher utility value was based on minimizing treatment and disease burden. Measures of treatment and disease burden included duration of suppressive antibiotics, number of invasive studies, pyelonephritis episodes, endoscopic treatments and open operations. All variables were varied spanning realistic ranges during sensitivity analyses to determine threshold values.
RESULTS: The protocol of no antibiotics or followup imaging yielded the best cost-utility for vesicoureteral reflux grades II and III. Sensitivity analysis of variables spanning realistic ranges demonstrated that utility penalties for invasive imaging and outpatient pyelonephritis were particularly important in determining the highest utility protocols, with threshold values ranging from -0.5 to -0.8.
CONCLUSIONS: In our models of treatment for vesicoureteral reflux a noninterventional approach constitutes the highest utility and least costly treatment for moderate grade reflux. Given the relative dearth of randomized trials, these analyses provide guidelines for current management of vesicoureteral reflux.

Entities:  

Mesh:

Year:  2007        PMID: 17222660     DOI: 10.1016/j.juro.2006.10.002

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Learning from history or the rationale for considering surgical correction of vesicoureteral reflux.

Authors:  Jonathan Riddell; Julie Franc-Guimond
Journal:  Can Urol Assoc J       Date:  2010-08       Impact factor: 1.862

2.  Cost-effectiveness of antimicrobial prophylaxis for children in the RIVUR trial.

Authors:  Lane S Palmer; Casey A Seideman; Yair Lotan
Journal:  World J Urol       Date:  2018-04-30       Impact factor: 4.226

3.  Estimating utility values for vesicoureteral reflux in the general public using an online tool.

Authors:  Jessica C Lloyd; Talitha Yen; Ricardo Pietrobon; John S Wiener; Sherry S Ross; Paul J Kokorowski; Caleb P Nelson; Jonathan C Routh
Journal:  J Pediatr Urol       Date:  2014-04-04       Impact factor: 1.830

4.  Utility Estimation for Pediatric Vesicoureteral Reflux: Methodological Considerations Using an Online Survey Platform.

Authors:  Rohit Tejwani; Hsin-Hsiao S Wang; Jessica C Lloyd; Paul J Kokorowski; Caleb P Nelson; Jonathan C Routh
Journal:  J Urol       Date:  2016-10-13       Impact factor: 7.450

5.  Injection volumes of dextranomer/hyaluronic acid are increasing in the endoscopic management of vesicoureteral reflux.

Authors:  Mathew D Sorensen; Martin A Koyle; Charles A Cowan; Ismael Zamilpa; Margarett Shnorhavorian; Thomas S Lendvay
Journal:  Pediatr Surg Int       Date:  2010-02-07       Impact factor: 1.827

Review 6.  Diagnosis and management of vesicoureteral reflux in children.

Authors:  Christopher S Cooper
Journal:  Nat Rev Urol       Date:  2009-08-11       Impact factor: 14.432

7.  Vesicoureteral reflux: current concepts and management implications.

Authors:  Sudipta Sen
Journal:  Indian J Pediatr       Date:  2008-11-21       Impact factor: 1.967

Review 8.  Health Economics of Antibiotics.

Authors:  Steven Simoens
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-29

9.  Cost-Utility of Antimicrobial Prophylaxis for Treatment of Children With Vesicoureteral Reflux.

Authors:  Nader Shaikh; Vinod Rajakumar; Caitlin G Peterson; Jillian Gorski; Anastasia Ivanova; Lisa Gravens Muller; Yosuke Miyashita; Kenneth J Smith; Tej Mattoo; Hans G Pohl; Ranjiv Mathews; Saul P Greenfield; Steven G Docimo; Alejandro Hoberman
Journal:  Front Pediatr       Date:  2020-01-10       Impact factor: 3.418

10.  The current evidence based medical management of vesicoureteral reflux: The Sickkids protocol.

Authors:  Sumit Dave; Antoine E Khoury
Journal:  Indian J Urol       Date:  2007-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.